eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2020
vol. 37
 
Share:
Share:
more
 
 
abstract:
Original paper

Management of psoriatic patients in biologic treatment associated with infectious comorbidities

Bernardini Nicoletta
1
,
Narcisi Alessandra
2, 3
,
Skroza Nevena
1
,
Ersilia Tolino
1
,
Daniela Colapietra
1
,
Mastroianni Claudio
4
,
Potenza Concetta
1

1.
Dermatology Unit “Daniele Innocenzi”, Department of MEDICO-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, Italy
2.
Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Rozzano-Milan, Italy
3.
Humanitas Clinical and Research Centre, Skin Pathology Lab, Rozzano-Milan, Italy
4.
Department of Public Health and Infectious Diseases, Azienda Ospedaliera Universitaria Policlinico Umberto I, Sapienza University of Rome, Italy
Adv Dermatol Allergol 2020; XXXVII (3): 417-421
Online publish date: 2020/07/16
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Psoriasis is a chronic inflammatory disease affecting about 2% of population, involving both acquired and innate immunity. Psoriasis affects mainly skin, presenting multiple co-morbidities; among them infective ones. Re-activation of tuberculosis or viral hepatitis (HBV and HCV) still represents a therapeutic challenge in patients receiving treatment with biological drugs, as well as HIV infection. For this reason, a multidisciplinary approach with global treatment resulting from active collaboration of different specialists is highly recommended.

Aim
To investigate the most common infective diseases as co-morbidities associated with psoriasis and to provide algorithms for screening, follow-up and therapeutic management in psoriatic patients.

Material and methods
We examined the main infectious comorbidities that can affect moderate to severe psoriatic patients, influencing the therapeutic choice as during the biological treatment both viral and tuberculosis re-activation may occur. We have therefore evaluated the main diseases (TB, Hepatitis B and C, HIV) and the monitoring of patients during treatment with biological agents.

Results
Regular monitoring of psoriatic patients is recommended during long-term treatment with biological drugs in order to identify cases of re-activation of the latent infective agent or de novo acquired infection.

Conclusions
Here we report the state of art regarding management of psoriatic patients with these co-morbidities suggesting a specific screening and management for infectious diseases in patients with moderate to severe plaque psoriasis.

keywords:

psoriasis, management, tuberculosis, infectious diseases

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe